● Recruiting

Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer

Condition: Pancreatic Ductal Adenocarcinoma · Sponsor: City of Hope Medical Center

PhaseN/A

Planned participants200

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This study aims to develop and validate a predictive microRNA (miRNA) panel to assess the response to neoadjuvant chemotherapy (NACT) in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC).

This description comes directly from the study's public registry record.

Talk to the study team

Ajay Goel, PhD · 626-218-3452 · ajgoel@coh.org

Always discuss trial participation with your own doctor first.

Locations (1)

City of Hope Medical Center

Duarte, California, United States

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07226154